An affiliate of the Georgia Institute of Technology, the Global Center for Medical Innovation (GCMI) helps verify, validate and accelerate commercialization of new medical technologies that save lives and improve patient care. From our Northyards and 14th Street facilities in midtown Atlanta, we help find the finish line for medtech innovations at any point on the pathway from bench to bedside.

Additionally, GCMI and T3 Labs proudly support BME Capstone teams with our medtech design, development and preclinical testing resources including facilities, staff, materials and know-how.

Principal investigators, faculty and student projects served include: Dr. Andres Garcia, Dr. Scott Hollister, Dr. Omer Inan, the Coulter Foundation, over 20 additional GT faculty members and dozens of BME Capstone teams.

This archive details just how we do that and to what effect.

Reducing the 90% Recurrence Rate for Glioblastoma Treatment Through an Implantable Device for the Delivery of Stem Cells

GCMI’s Spring 2023 Capstone Spotlight on Team LifeSTEM “Gliomas are brain tumors that come in multiple forms ranging from low-grade, benign tumors to high-grade, malignant tumors including glioblastomas. Glioblastoma treatment involves surgical resection, chemotherapy, and radiation. However, these tumors are typically incompletely resected, so there is a 90% recurrence rate [for a course of treatment,…

Taking a Bite Out of a 9.5% ORIF Re-Operation Rate

“X-rays supporting our testing at GCMI and T3 Labs clearly showed where the device engaged and the tip aligned at the bone level. This kind of evidence is important for our design history file, something that should make our regulatory journey and overall commercialization pathway more efficient.”

Center for Medtech Excellence Shares 2023, 2024 Cohort Dates

Medtech startups or established businesses looking to scale are encouraged to apply for one of the upcoming 16-week accelerator cohorts at the Center for MedTech Excellence. Launched in September 2022, the Center for Medtech Excellence catalyzes the development and commercialization of breakthrough biotechnology, medical devices, life science and therapeutic innovations. Primary areas of focus include…

Funding Support for GT Innovators and Researchers with Promising Medical Technologies

Funding varies in specific levels from fiscal year to fiscal year, specifically supports projects with high potential for successful commercialization, follow on funding and improved patient outcomes. Projects are selected by GCMI leadership in consultation with the board of directors. These funds are not for staff / salary or lab support. 

You’re a researcher or engineer who has found a solid unmet clinical need. Excellent! Now the rigorous work begins.

You’re a researcher or engineer who has found a clinician with a strong unmet clinical need your technology might solve.   Outstanding! Too many technologies go looking for problems to solve instead of finding the clinically stated problem first and fitting your technology to meet it in a way that truly works in the clinical…

Stars Align – Stridelink quickens march to commercialization with remote monitoring capabilities, CMS CPT codes

The team’s work to date, from concept to the technology’s current state, had primed it to seize the opportunity presented by the January 2022 Centers for Medicare and Medicaid Services (CMS) announcement of five new remote therapeutic monitoring CPT codes.

Early, consistent focus on the unmet need keeps Augment Health on a solid commercialization pathway

“When your ‘north star’ is doing what’s right for the patient and the user, everything else can follow. The best way to accelerate clinical adoption and utility is to prove your early hypotheses, generate data and gather clinical input.”

A Scalable, Customized Solution to an Unmet Clinical Need Long in Need of Innovation

“The failure of existing products on the market to successfully accomplish the needs of patients and clinicians made this a problem we addressed with enthusiasm and with the support and encouragement of Dr. Emily Blum and Dr. Jenelle Foote.”